Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Score 3
1992 pubmed

Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.

Goth. M I MI; Lyons. C E CE; Canny. B J BJ; Thorner. M O MO

Key Findings

  • Both GHRP (GRF‑1‑29) and PACAP stimulate GH release in a dose‑dependent way, with PACAP being more potent.
  • GHRP increases the number of GH‑secreting pituitary cells but does not change how much hormone each cell releases.
  • PACAP boosts both the number of secreting cells and the amount of GH each cell produces.
  • Somatostatin suppresses GH release mainly by reducing the number of active cells, and specific antagonists only block their own peptide’s effect.

Practical Outcomes

  • GRF‑1‑29 can be used to modestly increase GH by recruiting more somatotropes, but it won’t amplify the hormone output per cell. Pairing it with a GHRH analog, which raises per‑cell secretion, might give a stronger overall GH boost. PACAP shows a superior effect but isn’t widely available for self‑experimentation.

Summary

The study shows that the peptide GRF‑1‑29 (a GHRP) can raise growth hormone (GH) levels by turning on more pituitary cells, but it doesn’t make each cell pump out more hormone. A related brain peptide, PACAP, is even stronger – it both recruits more cells and makes each cell release more GH. All of these effects can be blocked by somatostatin, and the drugs that block GHRP or GHRH only stop their own specific pathway.

Abstract

GH secretion has been thought traditionally to be regulated by the two hypothalamic hormones, GH-releasing hormone (GHRH) and somatostatin (SRIF). Recent evidence has suggested that other factors may be involved. These factors include the natural ligand for the synthetic hexapeptide GH-releasing peptide (GHRP) and the putative hypophysiotropic factor pituitary adenylate cyclase-activating polypeptide (PA-CAP). Accordingly, we examined the effects of GHRP and PACAP on GH secretion at the single cell level using the reverse hemolytic plaque assay which allows distinction of effects on the number of secreting cells and the amount of hormone each cell secretes. Both factors stimulated GH secretion in a dose-dependent fashion, with PACAP being more effective. PACAP increased both the number of cells secreting and the mean amount of hormone secreted per cell. In contrast, GHRP increased the number of secreting cells, although it had no effect on the amount of secretion per cell. GH secretion induced by GHRH, GHRP, and PACAP was inhibited by SRIF, but the effect was predominantly on the number of cells secreting rather than the amount secreted per cell. Specific antagonists to GHRP and GHRH inhibited GH secretion induced by the respective agonist but not that induced by the other factor nor by PACAP. These findings confirm the complex nature of the regulation of GH secretion at the level of the somatotrope. At least three factors, operating via distinct receptors, are able to increase GH secretion. In addition, they ascribe a potential physiological role for the hitherto putative hypophysiotropic factor PACAP.

Study Information

Provider

pubmed

Year

1992

DOI

10.1210/endo.130.2.1346381